|
|
Volumn 214, Issue 1-2, 2005, Pages 151-161
|
|
Present and future of cancer vaccines
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CANCER ANTIBODY;
CANCER TESTIS ANTIGEN;
CANCER VACCINE;
CD4 ANTIGEN;
CELL PROTEIN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;
FATE BJ HCC 2 ANTIGEN;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
HCA 587 ANTIGEN;
HCA 661 ANTIGEN;
HEAT SHOCK PROTEIN;
HLA A1 ANTIGEN;
IMMUNOLOGICAL ADJUVANT;
INTERLEUKIN 2 RECEPTOR ALPHA;
ISCOMATRIX;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;
MELANOCYTE DIFFERENTIATION PROTEIN;
MELANOMA ANTIGEN;
MELANOMA ANTIGEN 1;
MELANOMA ANTIGEN 3;
MONTANIDE ISA 51;
NATURAL KILLER CELL RECEPTOR NKG2D;
NY ESO 1 ANTIGEN;
POXVIRUS VACCINE;
TPTE BJ HCC 5 ANTIGEN;
TRANSCRIPTION FACTOR FOXP3;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VIRUS VECTOR;
ZNF 165 ANTIGEN;
ANTIBODY RESPONSE;
CANCER;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNIZATION;
CANCER PREVENTION;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
CONFERENCE PAPER;
CYTOTOXIC T LYMPHOCYTE;
DRUG DESIGN;
DRUG TARGETING;
HUMAN;
IMMUNOGENICITY;
LIVER CELL CARCINOMA;
LUNG CANCER;
LUNG SMALL CELL CANCER;
NATURAL KILLER CELL;
NEUROECTODERM;
NONHUMAN;
OVARY CANCER;
POXVIRUS;
PRIORITY JOURNAL;
PROTEIN FUNCTION;
RECEPTOR UPREGULATION;
T LYMPHOCYTE;
T LYMPHOCYTE ACTIVATION;
TUMOR IMMUNITY;
TUMOR REGRESSION;
TUMOR REJECTION;
ANIMALS;
CANCER VACCINES;
DENDRITIC CELLS;
HUMANS;
KILLER CELLS, NATURAL;
NEOPLASMS;
T-LYMPHOCYTES;
POXVIRIDAE;
|
|
EID: 25644458517
PISSN: 0300483X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.tox.2005.06.004 Document Type: Conference Paper |
|
Times cited : (6)
|
|
References (0)
|
